Antonello Veccia, Umberto Basso, Carlo Cattrini, Paola Ermacora, Marco Maruzzo, Martina Alberti, Cecilia Anesi, Davide Bimbatti, Massimiliano Cani, Veronica Crespi, Giovanni Farinea, Dzenete Kadrija, Stefania Kinspergher, Eleonora Lai, Ludovica Lay, Francesca Maines, Alessia Mennitto, Francesco Pierantoni, Alessandro Samuelly, Susanna Urban, Orazio Caffo, Consuelo Buttigliero
{"title":"雄激素受体信号抑制剂作为一线治疗mCRPC的长期疗效的预后因素。","authors":"Antonello Veccia, Umberto Basso, Carlo Cattrini, Paola Ermacora, Marco Maruzzo, Martina Alberti, Cecilia Anesi, Davide Bimbatti, Massimiliano Cani, Veronica Crespi, Giovanni Farinea, Dzenete Kadrija, Stefania Kinspergher, Eleonora Lai, Ludovica Lay, Francesca Maines, Alessia Mennitto, Francesco Pierantoni, Alessandro Samuelly, Susanna Urban, Orazio Caffo, Consuelo Buttigliero","doi":"10.1080/14796694.2025.2497749","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Androgen receptor signaling inhibitors (ARSI) demonstrated to be efficacious as first-line therapy for mCRPC. The present real-world study aimed to identify the characteristics of the long-term responders (LTR) patients to first-line ARSI.</p><p><strong>Methods: </strong>We retrospectively reviewed a consecutive series of 622 mCRPC patients treated with one ARSI as first line. Patients received standard doses of abiraterone (1000 mg daily plus prednisone 10 mg daily) or enzalutamide (160 mg daily) until progression. Patients with an ARSI exposure ≥ 36 months were considered as LTR.</p><p><strong>Results: </strong>We identified 99 LTR patients who were compared to 523 no-LTR patients. At the multivariable analysis, LTR patients showed younger age (<i>p</i> < 0.0001), longer time to mCRPC (<i>p</i> < 0.0001), higher baseline levels of hemoglobin (<i>p</i> = 0.007), lower baseline PSA levels (<i>p</i> = 0.03), longer PSA doubling time (<i>p</i> = 0.03), low number of bone metastases (<i>p</i> = 0.01), and receivedenzalutamide (<i>p</i> = 0.01). The median overall survival (OS) of LTR was 78.2 months (95% CI 72.3-84.1 months) vs 27.7 months of no-LTR (95% CI 25.9-29.6 months).</p><p><strong>Conclusions: </strong>Several clinical and biological factors allow to identify those patients with higher probability of becoming LTR to ARSI in first-line mCRPC setting.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1647-1653"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140444/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC.\",\"authors\":\"Antonello Veccia, Umberto Basso, Carlo Cattrini, Paola Ermacora, Marco Maruzzo, Martina Alberti, Cecilia Anesi, Davide Bimbatti, Massimiliano Cani, Veronica Crespi, Giovanni Farinea, Dzenete Kadrija, Stefania Kinspergher, Eleonora Lai, Ludovica Lay, Francesca Maines, Alessia Mennitto, Francesco Pierantoni, Alessandro Samuelly, Susanna Urban, Orazio Caffo, Consuelo Buttigliero\",\"doi\":\"10.1080/14796694.2025.2497749\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>Androgen receptor signaling inhibitors (ARSI) demonstrated to be efficacious as first-line therapy for mCRPC. The present real-world study aimed to identify the characteristics of the long-term responders (LTR) patients to first-line ARSI.</p><p><strong>Methods: </strong>We retrospectively reviewed a consecutive series of 622 mCRPC patients treated with one ARSI as first line. Patients received standard doses of abiraterone (1000 mg daily plus prednisone 10 mg daily) or enzalutamide (160 mg daily) until progression. Patients with an ARSI exposure ≥ 36 months were considered as LTR.</p><p><strong>Results: </strong>We identified 99 LTR patients who were compared to 523 no-LTR patients. At the multivariable analysis, LTR patients showed younger age (<i>p</i> < 0.0001), longer time to mCRPC (<i>p</i> < 0.0001), higher baseline levels of hemoglobin (<i>p</i> = 0.007), lower baseline PSA levels (<i>p</i> = 0.03), longer PSA doubling time (<i>p</i> = 0.03), low number of bone metastases (<i>p</i> = 0.01), and receivedenzalutamide (<i>p</i> = 0.01). The median overall survival (OS) of LTR was 78.2 months (95% CI 72.3-84.1 months) vs 27.7 months of no-LTR (95% CI 25.9-29.6 months).</p><p><strong>Conclusions: </strong>Several clinical and biological factors allow to identify those patients with higher probability of becoming LTR to ARSI in first-line mCRPC setting.</p>\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"1647-1653\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140444/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2025.2497749\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2497749","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的：雄激素受体信号抑制剂（ARSI）作为一线治疗mCRPC有效。目前的现实世界研究旨在确定一线ARSI的长期应答（LTR）患者的特征。方法：我们回顾性回顾了连续622例以ARSI作为一线治疗的mCRPC患者。患者接受标准剂量的阿比特龙（每日1000毫克加强的松每日10毫克）或恩扎鲁胺（每日160毫克）直至病情进展。ARSI暴露≥36个月的患者被认为是LTR。结果：我们确定了99例LTR患者，与523例非LTR患者进行了比较。在多变量分析中，LTR患者表现为年龄更年轻（p = 0.007）， PSA基线水平较低（p = 0.03）， PSA倍增时间较长（p = 0.03），骨转移数量较少（p = 0.01），并且接受了登扎鲁胺（p = 0.01）。LTR的中位总生存期（OS）为78.2个月（95% CI 72.3-84.1个月），而非LTR的中位总生存期为27.7个月（95% CI 25.9-29.6个月）。结论：在一线mCRPC中，一些临床和生物学因素可以识别出那些更有可能成为LTR到ARSI的患者。
Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC.
Aim: Androgen receptor signaling inhibitors (ARSI) demonstrated to be efficacious as first-line therapy for mCRPC. The present real-world study aimed to identify the characteristics of the long-term responders (LTR) patients to first-line ARSI.
Methods: We retrospectively reviewed a consecutive series of 622 mCRPC patients treated with one ARSI as first line. Patients received standard doses of abiraterone (1000 mg daily plus prednisone 10 mg daily) or enzalutamide (160 mg daily) until progression. Patients with an ARSI exposure ≥ 36 months were considered as LTR.
Results: We identified 99 LTR patients who were compared to 523 no-LTR patients. At the multivariable analysis, LTR patients showed younger age (p < 0.0001), longer time to mCRPC (p < 0.0001), higher baseline levels of hemoglobin (p = 0.007), lower baseline PSA levels (p = 0.03), longer PSA doubling time (p = 0.03), low number of bone metastases (p = 0.01), and receivedenzalutamide (p = 0.01). The median overall survival (OS) of LTR was 78.2 months (95% CI 72.3-84.1 months) vs 27.7 months of no-LTR (95% CI 25.9-29.6 months).
Conclusions: Several clinical and biological factors allow to identify those patients with higher probability of becoming LTR to ARSI in first-line mCRPC setting.
期刊介绍：
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
